Dallah Healthcare Co. announces its Interim Financial results for the Period Ending on 2026-03-31 ( Three Months )

This revenue growth was driven by an increase in the number of patient visits across the Group’s facilities, particularly at Dallah Al-Khobar Hospital and Dallah Al-Ahsa Hospital, reflecting the positive impact of the acquisitions on the group’s revenue growth during the current quarter. Total patient visits rose by 27.5% to reach 936 thousand visits, compared to 734 thousand visits in the same quarter of the previous year, an increase of approximately 202 thousand visits. This revenue growth was achieved despite the current quarter being significantly affected by seasonality in the healthcare sector, due to the higher number of Eid Al-Fitr and school holiday days compared to the same period last year. This underscores the Group’s ability to offset seasonal factors through operational expansion resulting from acquisitions, as well as growth in its pre-existing medical facilities.

Dallah Al-Khobar Hospital and Dallah Al-Ahsa Hospital achieved significant revenue growth after operating under the Dallah Health umbrella. Their revenue for Q1 2026 increased by 50% compared to Q1 2025 (noting that Dallah Health’s financials in Q1 2025 accounted for 8 days only of the revenues of these two hospitals as the acquisition was completed on March 23, 2025).

• Non-recurring Item in Q1 2025: In Q1 2025, the Company participated in a real estate fund with a 33.33% stake through an in-kind contribution of land. This resulted in a recorded gain of SAR 51 million during the first quarter of 2025.

• Increase in financing costs and operating expenses during the first quarter of 2026 amounting to SR 64 million, the majority of which is attributable to the consolidation of the results of Dallah Al Khobar Hospital and Dallah Al Ahsa Hospital within the Group’s consolidated financial statements during the current quarter, compared to the corresponding quarter of 2025, which included the results of the two hospitals for only eight days as a result of completing the acquisition transaction on 23 March 2025.

• The Company was able to achieve growth in revenues, supported by the positive impact of the acquisitions and the operational growth of the facilities existing prior to the acquisition, which was reflected in an increase in gross profit of SR 36 million during the current quarter compared to the corresponding quarter of the previous year.

• Net profit before financing costs, depreciation, amortization, and Zakat (EBITDA)—adjusted by non-recurring gain—rose by 7% in Q1 2026 to reach SAR 194 million, compared to SAR 181 million in Q1 2025, an increase of SAR 13 million.

• It is worth noting that the net profit attributable to the Company’s shareholders achieved during the current quarter is in line with the expectations reflected in the Company’s budget for the year 2026, which took into consideration, as part of its preparation assumptions, the seasonality factors of the business activity.

Despite this seasonal impact, the Company maintained revenue above SR 1 billion during the current quarter, reflecting the strength of the Group’s operating revenue base and the resilience of its performance during seasonally low-activity periods. This was supported by the continued benefits from strategic expansions and increased operating capacity, both in the existing and acquired medical facilities, which contributed to mitigating the impact of seasonal factors on the Group’s overall revenues.

-The decline in revenues during the current quarter, which resulted in a decrease in gross profit of SR 64 million compared to the previous quarter, due to the current quarter being affected by the usual seasonal factors in the healthcare sector compared to the previous quarter, as it coincided with the holy month of Ramadan, the Eid Al-Fitr holiday, and the extended school holidays during the quarter. This also affected the performance of the associates (all operating in the healthcare sector) by approximately SR 9 million. On the other hand, the Company succeeded in reducing the Group’s operating and financing costs by SR 44 million.

-EBITDA in the first quarter of 2026 decreased by 18% to reach SR 194 million, compared to SR 237 million in the previous quarter, representing a decrease of SR 43 million.

-It is worth noting that the net profit attributable to the Company’s shareholders achieved during the current quarter is in line with the expectations reflected in the Company’s budget for the year 2026, which took into consideration, as part of its preparation assumptions, the seasonality factors of the business activity.